A Prospective Study of in-Office Diagnostic Vitreous Sampling in Patients With Vitreoretinal Pathology

Pfahler, Scott M.; Brandford, Angela N.; Glaser, Bert M.

doi:10.1097/iae.0b013e3181a2c1eb

Cited by 16 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 2 , 7 , 10 , 20 , 21 Office-based aspiration of vitreous sample for proteomic analysis has less commonly been used. 27 Despite theoretical risks of vitreoretinal traction, a large review of in-office vitreous sampling by Pfahler et al 18 showed that aspiration of small volumes was a safe and reproducible procedure. Lobo and Lightman 28 reported a similar rate, 92%, of obtaining adequate sample from vitreous aspiration and few complications in diagnosing patients with infectious, malignant, and inflammatory causes of uveitis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Feasibility of Quantitative Multiplexed Cytokine Analysis From Office-Based Vitreous Aspiration

Ghodasra

Fante

Gardner

et al. 2016

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PurposeThe goals of this study were to evaluate the safety of office-based vitreous sampling, and determine the utility of these samples with multiplex cytokine analysis.MethodsVitreous samples were collected from office-based needle aspiration and the rate of adverse events during follow-up was reviewed. The vitreous cytokine concentrations in a subset of patients with diabetic macular edema (DME) were analyzed using a 42 plex-cytokine bead array. These results were compared with vitreous cytokine concentrations in proliferative diabetic retinopathy (PDR) and controls (macular hole, epiretinal membrane, symptomatic vitreous floaters) from pars plana vitrectomy.ResultsAn adequate volume of vitreous fluid (100–200 μL) was obtained in 52 (88%) of 59 office-based sampling attempts. The average length of follow-up was 300 days (range, 42–926 days). There were no complications, including cataract, retinal tear or detachment, and endophthalmitis. Two patients (3%) had posterior vitreous detachments within 3 months. Vitreous cytokine concentrations were measured in 44 patients: 14 controls, 13 with DME, and 17 with PDR. The concentration of ADAM11, CXCL-10, IL-8, and PDGF-A were higher in PDR compared with controls and DME. The concentration of IL-6 was higher in PDR compared with controls, but not compared with DME.ConclusionsOffice-based vitreous aspiration is safe and yields high-quality samples for multiplex vitreous cytokine analysis. Significant elevations of vitreous cytokines were found in PDR compared with DME and controls, including the novel finding of elevated ADAM11. As such, office-based aspiration is a safe and effective means to identify vitreous factors associated with vitreoretinal disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Giansanti et al 17 reported that microsampling of small volumes (10–15 μL) in rabbit eyes is a useful technique in vitreous pharmacokinetic studies. Pfahler et al 18 found very few complications with a large number of in-office vitreous sampling attempts, but did not report on the ability to analyze samples acquired in this manner.…”

mentioning

confidence: 99%

Safety and Feasibility of Quantitative Multiplexed Cytokine Analysis From Office-Based Vitreous Aspiration

Ghodasra

Fante

Gardner

et al. 2016

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…1A ). 20 , 21 We reported that needle biopsies are comparable to vitreous cutter biopsies. 14 A prospective case series of patients undergoing this office-based aspiration demonstrated the method to be reproducible and safe with an average of 100 to 200 μL undiluted vitreous obtained in 88% of patients.…”

Section: Liquid Biopsy Techniques For Ophthalmic Tissuesmentioning

confidence: 94%

Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease

Vélez

Tang

Cabral

et al. 2018

Trans. Vis. Sci. Tech.

View full text Add to dashboard Cite

Proteomic analysis is an attractive and powerful tool for characterizing the molecular profiles of diseased tissues, such as the vitreous. The complexity of data available for analysis ranges from single (e.g., enzyme-linked immunosorbent assay [ELISA]) to thousands (e.g., mass spectrometry) of proteins, and unlike genomic analysis, which is limited to denoting risk, proteomic methods take snapshots of a diseased vitreous to evaluate ongoing molecular processes in real time. The proteome of diseased ocular tissues was recently characterized, uncovering numerous biomarkers for vitreoretinal diseases and identifying protein targets for approved drugs, allowing for drug repositioning. These biomarkers merit more attention regarding their therapeutic potential and prospective validation, as well as their value as reproducible, sensitive, and specific diagnostic markersTranslational RelevancePersonalized proteomics offers many advantages over alternative precision-health platforms for the diagnosis and treatment of vitreoretinal diseases, including identification of molecular constituents in the diseased tissue that can be targeted by available drugs.

show abstract

“…A study of 578 in-office vitreous aspiration procedures demonstrated that this technique is safe and reproducible with a high yield of successful samples (95%) [70]. Vitreous sampling does not expose the patient to additional office visits or setup, and it can be performed prior to intravitreal injection.…”

Section: Treatment Of Diabetic Retinopathymentioning

confidence: 99%

Current and future management of diabetic retinopathy: a personalized evidence-based approach

Fante

Gardner

Sundstrom

2013

Diabetes Management

View full text Add to dashboard Cite

Summary Diabetic retinopathy (DR) is the leading cause of new-onset blindness in working-age individuals in the USA and represents a growing worldwide epidemic. Classic risk factors for onset or progression of DR include poor glycemic control, hypertension and hyperlipidemia; however, these factors account for only a small proportion of the risk of DR. New systemic risk factors are emerging, which may allow for personalized risk profiling and targeted treatment by physicians. In addition, early studies of vitreous fluid in patients with DR have resulted in a new paradigm: diabetes causes inflammation in the retina, which is mediated by multiple small signaling molecules that induce angiogenesis and vascular permeability. Future treatment of DR may involve two approaches: early vitreous analysis, followed by drug treatment targeted to the unique vitreous composition of the patient; and collaboration between ophthalmologists and primary care providers to address the unique systemic risk profile of each diabetic patient.

show abstract

A Prospective Study of in-Office Diagnostic Vitreous Sampling in Patients With Vitreoretinal Pathology

Abstract: This prospective study has shown that in-office vitreous sampling of 50 microL to 100 microL is a safe and reproducible procedure. Larger randomized studies will be helpful to further assess the safety and long-term effects of in-office diagnostic vitreous sampling.

Cited by 16 publications

References 8 publications

Safety and Feasibility of Quantitative Multiplexed Cytokine Analysis From Office-Based Vitreous Aspiration

Safety and Feasibility of Quantitative Multiplexed Cytokine Analysis From Office-Based Vitreous Aspiration

Personalized Proteomics for Precision Health: Identifying Biomarkers of Vitreoretinal Disease

Current and future management of diabetic retinopathy: a personalized evidence-based approach

Contact Info

Product

Resources

About